American Association for Cancer Research
10780432ccr140464-sup-127593_3_supp_2668028_nc5s33.png (902.4 kB)

Supplementary Figure 5 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer

Download (902.4 kB)
posted on 2023-03-31, 19:08 authored by Louisa S. Chard, Eleni Maniati, Pengju Wang, Zhongxian Zhang, Dongling Gao, Jiwei Wang, Fengyu Cao, Jahangir Ahmed, Margueritte El Khouri, Jonathan Hughes, Shengdian Wang, Xiaozhu Li, Bela Denes, Istvan Fodor, Thorsten Hagemann, Nicholas R. Lemoine, Yaohe Wang

Supplementary Figure 5. Analysis of B, Treg, NK and NKT cells in splenocytes of DT6606-OVA tumor-bearing mice after treatment.



Purpose: Vaccinia virus has strong potential as a novel therapeutic agent for treatment of pancreatic cancer. We investigated whether arming vaccinia virus with interleukin-10 (IL10) could enhance the antitumor efficacy with the view that IL10 might dampen the host immunity to the virus, increasing viral persistence, thus maximizing the oncolytic effect and antitumor immunity associated with vaccinia virus.Experimental Design: The antitumor efficacy of IL10-armed vaccinia virus (VVLΔTK-IL10) and control VVΔTK was assessed in pancreatic cancer cell lines, mice bearing subcutaneous pancreatic cancer tumors and a pancreatic cancer transgenic mouse model. Viral persistence within the tumors was examined and immune depletion experiments as well as immunophenotyping of splenocytes were carried out to dissect the functional mechanisms associated with the viral efficacy.Results: Compared with unarmed VVLΔTK, VVLΔTK-IL10 had a similar level of cytotoxicity and replication in vitro in murine pancreatic cancer cell lines, but rendered a superior antitumor efficacy in the subcutaneous pancreatic cancer model and a K-ras-p53 mutant-transgenic pancreatic cancer model after systemic delivery, with induction of long-term antitumor immunity. The antitumor efficacy of VVLΔTK-IL10 was dependent on CD4+ and CD8+, but not NK cells. Clearance of VVLΔTK-IL10 was reduced at early time points compared with the control virus. Treatment with VVLΔTK-IL10 resulted in a reduction in virus-specific, but not tumor-specific CD8+ cells compared with VVLΔTK.Conclusions: These results suggest that VVLΔTK-IL10 has strong potential as an antitumor therapeutic for pancreatic cancer. Clin Cancer Res; 21(2); 405–16. ©2014 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager